Superiority Trial of Aphasia-focused Rehabilitation with tDCS Stimulation

Date Added
November 6th, 2025
PRO Number
Pro00147406
Researcher
Janina Wilmskoetter

List of Studies


Keywords
Language, Stroke Recovery
Summary

The purpose of this study to help us understand if adding transcranial Direct Current
Stimulation (tDCS), a non-invasive brain stimulation technique, to Speech Therapy
improves language recovery in people with Broca's aphasia and is more effective than Speech Therapy alone.

Institution
MUSC
Recruitment Contact
Stephanie Cute
843-792-7049
cute@musc.edu

Pilot Trial of Written Exposure Therapy Delivered via Telehealth to Adolescents with Posttraumatic Stress Disorder

Date Added
November 4th, 2025
PRO Number
Pro00147573
Researcher
Emily Tilstra-Ferrell

List of Studies

Keywords
Adolescents, Mental Health
Summary

Written Exposure Therapy (WET) is a five-session mental health therapy for post-traumatic stress disorder (PTSD). Research shows that it works as well as longer treatments for PTSD among people over 18, even though it requires fewer sessions than other PTSD therapies. However, WET has not been adapted and tested via telehealth with people aged 12 to 18. Our study aims to see how WET can be adapted to meet the needs of people aged 12 to 18 who have experienced trauma and currently have PTSD symptoms. To adapt WET for this age group, first we will talk with PTSD experts and people aged 12 to 18 to learn what changes might make WET more suitable for young people. We'll also deliver WET via telehealth to five people aged 12 to 18 following the manual as it is written for people over age 18 to see what needs adjusting. In the next part of the study, we will offer the adapted version of WET via telehealth to 20 people aged 12 to 18 in our MUSC integrated pediatric primary care clinic. People aged 12 to 18 will take part in five to seven weekly online therapy sessions and three virtual study visits (before therapy, after therapy, and one month later) to better understand who they are as a person and their current mental health symptoms and diagnoses. Individuals who are 18 can participate without caregiver permission; individuals aged 12 to 17 can only participate with caregiver permission. Our goal is to find the best way to provide effective PTSD treatment for young people that can be delivered in real-world pediatric primary care settings, so that ultimately more people can get the help they need after traumatic experiences.

Institution
MUSC
Recruitment Contact
Owen Winters
843-792-2615
winterso@musc.edu

A pragmatic remote approach to improve transitions of care and retention in opioid use disorder treatment.

Date Added
November 4th, 2025
PRO Number
Pro00146867
Researcher
Allison Smith

List of Studies


Keywords
Psychiatry, Substance Use
Summary

This is a small, test study to see if mailing buprenorphine works for patients with opioid use disorder and a recent medical hospitalization. It tries to remove some of the existing barriers to make it easier to stay in treatment and make it easier for individuals to keep taking their medicine after discharge. The purpose of this research study is to determine if mailing buprenorphine is possible, acceptable, and look at the early results of how well it works.

Institution
MUSC
Recruitment Contact
Hannah Schneider
843-580-8243
schneidh@musc.edu

Autism & Self-regulation: Tele-Assessment of Autonomic Psychophysiological correlates (ASAP)

Date Added
November 4th, 2025
PRO Number
Pro00146541
Researcher
Rosmary Ros-Demarize

List of Studies


Keywords
Autism, Children's Health
Summary

This study aims to evaluate the remote delivery of self-regulation assessments in young children with autism and their parents. Parents will complete online surveys. Parents and children will complete two virtual visits. At the second visit, participants will wear a heart rate monitor while completing study tasks. This study will inform research on behavioral therapies for children with autism.

Institution
MUSC
Recruitment Contact
Alexandra Marsden
843-714-1352
autismresearch@musc.edu

Multi Cancer Early Detection Biorepository

Date Added
October 29th, 2025
PRO Number
Pro00146813
Researcher
Gerard Silvestri

List of Studies


Keywords
Cancer
Summary

This study will enroll patients and collect blood samples from those who have a newly diagnosed cancer, are going to a procedure for a definitive diagnosis of cancer, or healthy control subjects. These samples that are being collected and banked will be used for future development of blood tests to detect lung cancer in future patients at the earliest stages.

Institution
MUSC
Recruitment Contact
Michael Balassone
843-792-6696
Balassom@musc.edu

Multi Cancer Early Detection Biorepository

Date Added
October 29th, 2025
PRO Number
Pro00146813
Researcher
Gerard Silvestri

List of Studies


Keywords
Cancer
Summary

This study will enroll patients and collect blood samples from those who have a newly diagnosed cancer, are going to a procedure for a definitive diagnosis of cancer, or healthy control subjects. These samples that are being collected and banked will be used for future development of blood tests to detect lung cancer in future patients at the earliest stages.

Institution
MUSC Health Florence Medical Center
Recruitment Contact
Michael Balassone
843-792-6696
Balassom@musc.edu

Multi Cancer Early Detection Biorepository

Date Added
October 29th, 2025
PRO Number
Pro00146813
Researcher
Gerard Silvestri

List of Studies


Keywords
Cancer
Summary

This study will enroll patients and collect blood samples from those who have a newly diagnosed cancer, are going to a procedure for a definitive diagnosis of cancer, or healthy control subjects. These samples that are being collected and banked will be used for future development of blood tests to detect lung cancer in future patients at the earliest stages.

Institution
MUSC Health Lancaster Medical Center
Recruitment Contact
Michael Balassone
843-792-6696
Balassom@musc.edu

Multi Cancer Early Detection Biorepository

Date Added
October 29th, 2025
PRO Number
Pro00146813
Researcher
Gerard Silvestri

List of Studies


Keywords
Cancer
Summary

This study will enroll patients and collect blood samples from those who have a newly diagnosed cancer, are going to a procedure for a definitive diagnosis of cancer, or healthy control subjects. These samples that are being collected and banked will be used for future development of blood tests to detect lung cancer in future patients at the earliest stages.

Institution
MUSC Health Columbia Medical Center
Recruitment Contact
Michael Balassone
843-792-6696
Balassom@musc.edu

Developing a communication support intervention for cancer caregivers in emerging and young adulthood

Date Added
October 29th, 2025
PRO Number
Pro00146111
Researcher
Amanda Kastrinos

List of Studies

Keywords
Cancer, Cancer/Brain, Cancer/Breast, Cancer/Gastrointestinal, Cancer/Genitourinary, Cancer/Leukemia, Cancer/Lung, Cancer/Lymphoma, Cancer/Myeloma, Cancer/Other, Cancer/Sarcoma, Cancer/Skin, Healthy Volunteer Studies
Summary

Cancer caregivers in emerging and young adulthood (ages 18-35) are an underresearched and unsupported group of caregivers, and yet they are not uncommon. To address this critical support gap, the goal of this study is to develop and pilot test a caregiving support intervention specifically tailored for emerging and young adults caring for a parent with cancer. This phase of the study is intended to capture feedback on the intervention via focus groups with emerging and young adult caregivers of a parent with cancer.

Institution
MUSC
Recruitment Contact
Amanda Kastrinos
843-876-9076
kastrinos@musc.edu

GAIN-BCG: Gemcitabine Alternating With Intravesical BCG Randomized Against BCG Alone For Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer

Date Added
October 28th, 2025
PRO Number
Pro00147104
Researcher
Robert Grubb

List of Studies


Keywords
Cancer/Genitourinary, Drug Studies
Summary

This study is for people with high-risk, non-muscle invasive bladder cancer that has returned after treatment with BCG. Your cancer either did not fully respond to BCG or came back after initially responding, which is called BCG-exposed NMIBC. The purpose of this study is to find out if adding a chemotherapy drug called gemcitabine, given directly into the bladder through a catheter, to BCG works better than BCG alone. In this study, you will either receive BCG alone for up to 6 weeks or gemcitabine plus BCG for up to 10 weeks, called induction therapy. If the treatment is effective, you may continue with maintenance therapy, which is either BCG alone or gemcitabine plus BCG given over several weeks. After treatment, your doctor will monitor you for 5 years with regular checkups, cystoscopies, and CT scans to watch for side effects or recurrence. The main risks are that the study treatment may not work as well as usual care, and it may cause side effects such as pain with urination, urinary urgency, blood in the urine, bladder inflammation, or urinary tract infection. There may also be risks that study doctors do not yet know about.
There will be a total of 17 patients enrolled locally over the course of 42 months.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu



-- OR --